HCC70 CDX Model

The HCC70 cell line is derived from human triple-negative breast cancer (TNBC), one of the most aggressive subtypes of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). HCC70 serves as a fundamental model for understanding the intricate biology of TNBC and for assessing potential therapeutic approaches. This cell line encapsulates many of the molecular features and genetic anomalies inherent to TNBC, underscoring its value for preclinical studies targeting this challenging breast cancer subtype. Through in vitro and in vivo experiments with HCC70, insights can be gleaned about TNBC’s aggressive growth patterns, metastatic tendencies, stromal interactions, and responsiveness to various therapeutic agents. Researchers rely on the HCC70 model to dissect the molecular underpinnings of TNBC and to develop and evaluate therapeutic strategies, especially those targeting the unique vulnerabilities of triple-negative tumors.

Model Details

Cancer Location: Mammary Fat Pad
Cancer Type: Triple-Negative Breast Cancer
Model Name: HCC70
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Paclitaxel)

HCC70 Growth curves

HCC70 CDX Model

Growth of orthotopic (MFP) HCC70 in Nu/Nu mice (n=6)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.